Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
15.10.2019 12:00:00 EEST | Business Wire | Press release
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it will present preclinical study results on the farnesoid X receptor (FXR) agonist TERN-101 at The Liver Meeting® 2019, being held by the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., November 8-12. The data demonstrate that in preclinical models, TERN-101 was preferentially delivered to the liver, which enables a robust, localized effect on FXR, while potentially mitigating non-liver mediated adverse effects.
The abstract (#2158), titled “Pharmacokinetics, tissue distribution and pharmacodynamics of TERN-101, a novel farnesoid X receptor (FXR) agonist, in preclinical species” will be presented as a poster on Monday, November 11, 2019.
“TERN-101 has the potential to be the backbone of future combination treatments for NASH due to its broad pleiotropic effects of FXR agonism on multiple pathogenetic mechanisms of NASH,” said Erin Quirk, M.D., Chief Medical Officer of Terns. “Our preclinical data show that TERN-101 is efficiently enriched in the liver, the target organ for FXR activity against NASH, which could potentially mitigate non-liver mediated tolerability issues associated with systemic FXR activation.”
TERN-101 has been advanced into clinical studies. A Phase 1 trial demonstrated clinical pharmacokinetic properties consistent with once-daily dosing. At The International Liver Congress™ 2019 in Vienna, Terns presented preclinical data demonstrating that TERN-101 reduced liver steatosis, inflammation, ballooning, and fibrosis in a preclinical model of non-alcoholic steatohepatitis (NASH).
TERN-101 and TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are both in development for the treatment of NASH and were initially discovered and developed by Eli Lilly and Company. Terns signed a global, exclusive agreement with Eli Lilly in 2018 to develop, manufacture, and commercialize TERN-101, TERN-201, and another preclinical candidate that inhibits an undisclosed NASH target.
About TERN-101 and Farnesoid X Receptor (FXR) Agonism
TERN-101 is a potent non-bile acid FXR agonist being developed as a therapeutic for NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation, and fibrosis. FXR agonism and activation has demonstrated improvement over placebo in regression of histological liver fibrosis without progression to NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NAFLD and NASH.
About NASH
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005032/en/
Contact information
US Media Contact:
Margaret Robinson
+1 (415) 690 0084
China Media Contact:
Zhou Zhou
+86 13482103703
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release
Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18 th and 19 th11.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a panel on November 19 at 10:30am GMT. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/eyqYNaU4UZTBAgMVip4JTx A live audio webcast of the panel will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/guest_book?session_id=H4EMMyKtX5Gd7TPGHGc3Si A replay of both webcasts will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) i
Lufthansa Selects Alcohol-Free Gewürztraminer Made with Solos Technology for Premium Allegris Business Class Experience11.11.2026 12:55:00 EET | Press release
Lufthansa has selected BREAKAWAY Gewürztraminer, an alcohol-free wine from German winery Bergdolt-Reif & Nett, for its Allegris Business Class. Made using Solos technology, the wine was chosen following a blind tasting and is scheduled to be served from November 2026 to January 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111810839/en/ BREAKAWAY Gewürztraminer by Bergdolt-Reif & Nett, made with Solos technology. The selection marks a milestone for both partners, bringing their expertise to Lufthansa's premium passengers. Where winemaking meets innovation BREAKAWAY Gewürztraminer is made from a late-harvest wine, chosen for its distinctive aromatic character. Bergdolt-Reif & Nett, a fifth-generation family winery in Germany's Palatinate region, has developed alcohol-free wines since 2022. "That the wine impressed in a blind tasting is the most important point for me," says Christian Nett, winemaker and Managing Dir
Quectel Expands 5G Antenna Portfolio With Ten Versatile Combo Solutions, From Compact 2-In-1 to Rugged 9-In-1 Designs11.11.2026 11:00:00 EET | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces ten external combo antennas that combine 5G with GNSS, Wi-Fi or both in a single housing. Instead of specifying, fitting and testing a separate antenna for each radio, device makers can choose one unit matched to the size, technology mix and operating environment of their deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111461614/en/ Quectel expands 5G antenna portfolio with ten versatile combo solutions, from compact 2-in-1 to rugged 9-in-1 designs Across the family, each antenna combines multiple omnidirectional elements with high isolation between them to limit self-interference. Most models cover 5G from 600MHz to 6000MHz and remain backward compatible with 4G, 3G, 2G, LTE Cat-M and NB-IoT networks. All support screw mounting, some also adhesive mounting, and housings are built for outdoor use with ratings from IP65 up to IP69K. “Ev
Quectel SP900BF-AP Smart Module Sets the Pace for Edge AI with 100 TOPS of Computing Power11.11.2026 11:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced the SP900BF-AP, a smart module that lets robots, inspection systems and edge gateways run large AI models on the device itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111252890/en/ Quectel SP900BF-AP smart module sets the pace for Edge AI with 100 TOPS of computing power Built on the Qualcomm Dragonwing™ IQ-9075 Processor and delivering up to 100 TOPS of on-device AI compute, the module enables industrial OEMs to integrate advanced AI directly into their products, reducing latency, bandwidth costs and data privacy risks associated with cloud-based processing. By processing data locally, manufacturers can support real-time robotics, automated inspection and other demanding industrial applications while retaining greater control over sensitive production data. Long-term hardware availability also helps meet the extended product l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom